AU2003286728A1 - Compounds for the treatment of metabolic disorders - Google Patents

Compounds for the treatment of metabolic disorders

Info

Publication number
AU2003286728A1
AU2003286728A1 AU2003286728A AU2003286728A AU2003286728A1 AU 2003286728 A1 AU2003286728 A1 AU 2003286728A1 AU 2003286728 A AU2003286728 A AU 2003286728A AU 2003286728 A AU2003286728 A AU 2003286728A AU 2003286728 A1 AU2003286728 A1 AU 2003286728A1
Authority
AU
Australia
Prior art keywords
compounds
treatment
metabolic disorders
metabolic
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003286728A
Other languages
English (en)
Other versions
AU2003286728A8 (en
Inventor
Kirvin L. Hodge
Shalini Sharma
Reid W. Von Borstel
Stephen D. Wolpe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Therapeutics Corp
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of AU2003286728A1 publication Critical patent/AU2003286728A1/en
Publication of AU2003286728A8 publication Critical patent/AU2003286728A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003286728A 2002-11-01 2003-10-28 Compounds for the treatment of metabolic disorders Abandoned AU2003286728A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42325302P 2002-11-01 2002-11-01
US60/423,253 2002-11-01
PCT/US2003/034185 WO2004041165A2 (en) 2002-11-01 2003-10-28 Compounds for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
AU2003286728A1 true AU2003286728A1 (en) 2004-06-07
AU2003286728A8 AU2003286728A8 (en) 2004-06-07

Family

ID=32312627

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003286728A Abandoned AU2003286728A1 (en) 2002-11-01 2003-10-28 Compounds for the treatment of metabolic disorders

Country Status (6)

Country Link
US (1) US7645772B2 (enExample)
EP (1) EP1556085A4 (enExample)
JP (1) JP2006507303A (enExample)
AU (1) AU2003286728A1 (enExample)
CA (1) CA2502297C (enExample)
WO (1) WO2004041165A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100344616C (zh) * 2001-06-12 2007-10-24 维尔斯达医疗公司 用于治疗代谢失调的化合物
KR101106631B1 (ko) * 2003-02-13 2012-01-20 웰스태트 테러퓨틱스 코포레이션 대사 질환의 치료용 화합물
PL1633340T3 (pl) 2003-04-15 2011-04-29 Wellstat Therapeutics Corp Związki do leczenia chorób metabolicznych
CA2521589C (en) 2003-04-22 2011-11-01 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR101192272B1 (ko) * 2003-04-30 2012-10-17 웰스태트 테러퓨틱스 코포레이션 대사 질환의 치료용 화합물
WO2005018628A1 (en) * 2003-08-20 2005-03-03 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP4995080B2 (ja) * 2004-05-14 2012-08-08 エミスフェアー・テクノロジーズ・インク 活性薬剤を送達するためのアリールケトン化合物および組成物
CA2602854C (en) * 2005-04-01 2013-05-14 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
UA95613C2 (ru) * 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
EP1976378A4 (en) * 2006-01-25 2010-06-09 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
JP2009531280A (ja) * 2006-01-25 2009-09-03 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物
KR20080089453A (ko) * 2006-01-25 2008-10-06 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
US20090176885A1 (en) * 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2009531288A (ja) * 2006-02-13 2009-09-03 ウェルスタット セラピューティクス コーポレイション 代謝障害の処置のための化合物
CN101394738A (zh) * 2006-02-28 2009-03-25 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
CN101410105A (zh) * 2006-03-31 2009-04-15 维尔斯达医疗公司 代谢紊乱的组合治疗
NZ572681A (en) * 2006-05-18 2012-01-12 Wellstat Therapeutics Corp Aromatic acetal carboxylic acid derivatives for the treatment of metabolic disorders
MX2008015640A (es) * 2006-06-09 2009-01-09 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
US20100227809A1 (en) * 2006-08-17 2010-09-09 Wellstat Therapeutics Corporation Combination treatment for metabolic disorders
EP2240024A4 (en) * 2008-01-15 2014-05-21 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
CA2716860C (en) 2008-03-13 2017-08-29 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5225734A (en) 1975-08-23 1977-02-25 Kyorin Pharmaceut Co Ltd Process for preparation of 4-(4'-halogenobenzyloxy)-bonzoyl acetate
JPS5515460A (en) 1978-07-20 1980-02-02 Hisamitsu Pharmaceut Co Inc Novel 2-substituted-benzoylpropionic acid derivative
JPS6140270A (ja) 1984-08-01 1986-02-26 Morishita Seiyaku Kk ピリダジノン誘導体
FR2752422B1 (fr) * 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
WO2001081340A2 (en) * 2000-04-24 2001-11-01 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
WO2002002119A1 (en) 2000-06-29 2002-01-10 Smithkline Beecham Corporation Fatty acid synthase inhibitors
WO2002059077A1 (en) 2001-01-26 2002-08-01 Takeda Chemical Industries, Ltd. Aminoethanol derivatives
CN100344616C (zh) * 2001-06-12 2007-10-24 维尔斯达医疗公司 用于治疗代谢失调的化合物
KR101106631B1 (ko) * 2003-02-13 2012-01-20 웰스태트 테러퓨틱스 코포레이션 대사 질환의 치료용 화합물
PL1633340T3 (pl) * 2003-04-15 2011-04-29 Wellstat Therapeutics Corp Związki do leczenia chorób metabolicznych
CA2602854C (en) 2005-04-01 2013-05-14 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
EP1556085A2 (en) 2005-07-27
WO2004041165A2 (en) 2004-05-21
JP2006507303A (ja) 2006-03-02
CA2502297A1 (en) 2004-05-21
US7645772B2 (en) 2010-01-12
WO2004041165A3 (en) 2005-02-03
EP1556085A4 (en) 2012-08-22
CA2502297C (en) 2011-12-13
US20060035970A1 (en) 2006-02-16
AU2003286728A8 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
IL209842A0 (en) Compounds for the treatment of metabolic disorders
ZA200504558B (en) Compounds for the treatment of metabolic disorders
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
AU2003249244A1 (en) Methods for the treatment of neoplasms
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
AU2003274342A1 (en) Compositions for the treatment of autoimmune disorders
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
AU2003295890A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
GB0329874D0 (en) Compounds useful for the treatment of diseases
AU2003256650A1 (en) Substituted thiophene carboxamide compounds for the treatment of inflammation
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2003223684A1 (en) Lxr modulators for the treatment of cardiovascular diseases
AU2003251875A1 (en) Combination therapy for the treatment of neoplasms
AU2003215150A1 (en) Therapeutic compounds
IL163871A0 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
AU2003220483A1 (en) Substituted pyrazolyl compounds for the treatment of inflammation
AU2003270683A1 (en) Compounds for the treatment of premature ejaculation
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
AU2003237460A1 (en) Combination treatments for purinoceptor-related disorders
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders
AU2003239967A1 (en) Compound for the treatment of cns disorders
AU2003243214A1 (en) Salts of bis-arylsulfones for the treatment of cns disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase